Background
Persistent portal hypertension after hepatitis C virus (HCV) cure remains a major determinant of prognosis in advanced cirrhosis, yet its immune drivers are poorly defined, particularly in people with HIV (PWH). Hepatic venous pressure gradient (HVPG) is the gold standard for assessing portal hypertension and a strong predictor of outcomes. Despite high rates of sustained virological response with direct-acting antivirals (DAAs), many patients show incomplete HVPG regression. Identifying baseline immune features conditioning post-cure recovery is essential for risk stratification and targeted therapies.
Methods
We conducted a prospective multicenter study within the Spanish ESCORIAL cohort with 41 individuals with advanced HCV-related cirrhosis (18 people without HIV [PWoH], 23 PWH) who achieved HCV cure with DAAs. All had baseline HVPG and follow-up at 48 weeks. Plasma biomarkers were quantified by multiplex immunoassay, and CD4+/CD8+ T-cell immunophenotyping by flow cytometry. Associations between baseline immune markers and HVPG changes were analyzed with generalized linear mixed-effects models, with q-values controlling for multiple testing.
Results
Baseline features differed: PWH were younger, mostly male, and more often had intravenous drug use, but baseline HVPG was comparable. Distinct immune signatures of impaired HVPG regression emerged by HIV status. In PWoH, incomplete regression associated with a proinflammatory cytokine profile [TNF-α (AMR=1.13; q=0.012), IL-17A (AMR=1.28; q=0.012), IL-10 (AMR=1.20; q=0.028)] and broad CD4+ activation [HLA-DR+ (AMR=1.44; q<0.001), CD38+HLA-DR+ (AMR=1.30; q=0.007)], especially within central memory (CM) and effector memory (EM) subsets. In PWH, impaired regression was linked to endothelial dysfunction [sVCAM-1 (AMR=1.58; q=0.096)] and restricted CD4+ activation in EM [HLA-DR+, q=0.030] and TemRA [CD38+HLA-DR+, q=0.030] subsets. CD8+ phenotypes showed no significant associations. Larger baseline CM CD4+ pool was protective only in PWoH (AMR=0.75; q=0.074).
Conclusions
HIV coinfection reshapes the immune determinants of post-cure portal hypertension recovery. In PWoH, systemic inflammation and broad CD4+ activation dominate, whereas in PWH, endothelial injury and restricted exhausted memory phenotypes prevail. The absence of the protective CM CD4+ compartment in PWH underscores profound immune exhaustion. These findings challenge a one-size-fits-all model and support stratified strategies to manage residual portal hypertension after HCV cure.